ASH 2023 | Cladribine + LDAC + venetoclax alternated with azacitidine + venetoclax in older patients with AML
Tapan Kadia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a prognostic analysis of a Phase II study (NCT03586609) assessing cladribine with low-dose cytarabine (LDAC) and venetoclax alternated with azacitidine and venetoclax in patients with newly diagnosed acute myeloid leukemia (AML). The study reported an encouraging overall response rate (ORR), overall survival (OS), and event-free survival (EFS) with this combination therapy despite this being an older patient population and many patients harboring high-risk mutations. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Pinotb-Bio: Consultancy; Amgen, Inc.: Research Funding; Daiichi Sankyo, Genentech, Inc., Genzyme, Jazz Pharmaceuticals, Liberum, Novartis, Pfizer, PinotBio, Inc, Pulmotect, Inc, Sanofi-Aventis, Servier: Consultancy; Pfizer: Consultancy, Research Funding; Glycomimetics: Research Funding; BMS: Consultancy, Research Funding; AstraZeneca: Research Funding; Astellas Pharma Global Development: Research Funding; Ascentage Pharma Group: Research Funding; Genentech: Consultancy, Research Funding; Servier: Consultancy; Cellenkos Inc.: Research Funding; Agios: Consultancy; Cyclacel: Research Funding; Celgene: Research Funding; Delta-Fly Pharma, Inc.: Research Funding; Cure: Speakers Bureau; AbbVie, Amgen, Inc, Ascentage Pharma Group, Astellas Pharma Global Development, Astex, AstraZeneca, BMS, Celgene, Cellenkos Inc, Cyclacel, Delta-Fly Pharma, Inc, Genentech, Inc., Genfleet, Glycomimetics, Iterion, Janssen Research and Development: Research Funding; Genzyme: Honoraria; Biologix, Cure, Hikma Pharmaceuticals: Speakers Bureau; Jazz Pharmaceuticals, Pfizer, Pulmotect, Inc, Regeneron Pharmaceuticals, SELLAS Life Sciences Group: Research Funding; GenFleet Therapeutics: Research Funding; Hikma Pharmaceuticals: Speakers Bureau; Iterion: Research Funding; Janssen Research and Development: Research Funding; Liberum: Consultancy; Novartis: Consultancy; Pulmotect, Inc.: Consultancy, Research Funding; Regeneron Pharmaceuticals: Research Funding; Sanofi-Aventis: Consultancy; SELLAS Life Sciences Group: Research Funding; Astex: Honoraria.
